Recolony logo

Recolony

Swiss start-up Recolony aims to develop an oral cancer medication using bacteria.

2-10 employees · est. 2022 · Zurich, Switzerland

VS
VacV Biotherapeutics logo

VacV Biotherapeutics

Developing oncolytic viruses as therapeutics for cancer

6 employees · est. 2022 · London, United Kingdom

Side-by-Side Comparison

Recolony VacV Biotherapeutics
Founded
2022 2022
Headquarters
Zurich, Switzerland London, United Kingdom
Employees
2-10 6
Industry
Biotechnology Biotechnology, Health Care, Life Sciences
Funding Stage
Grant Seed
Total Funding
$160.00K $3.00M
Funding Rounds
2 1
Services
Not tracked yet Not tracked yet
Target Customers
Not tracked yet Not tracked yet
Taxonomy
Swiss Start-up, Recolony, Biotech, Oral Cancer, Medication, Bacteria-based, Colorectal Cancer, Microbial Solution, Therapy, Biotech Start-up, Cancer Treatment, Switzerland, Bacteria, Prevention, Treatment Biotech, Cancer Immunotherapy, Oncolytic Virus, Viral-based Therapy, Tumor-specificity, Neurotoxicity, Therapeutic Potential, EEV Production, Biopharmaceuticals, Treatment Innovation
Website
recolony.ch vacvbtx.com
Recolony logo

About Recolony

Recolony is a Swiss biotech startup founded in 2022 with a promising goal - to develop a bacteria-based oral medication for treating and preventing cancer. Their flagship product, Recolony, offers a microbial solution specifically targeting colorectal cancer. This innovative approach holds tremendou...

VacV Biotherapeutics logo

About VacV Biotherapeutics

VacV Biotherapeutics, with the slogan "Developing oncolytic viruses as therapeutics for cancer," is a UK-based startup founded in 2022. The company, led by cancer immunotherapy experts Professor Yaohe Wang, Professor Nicholas Lemoine, Dr. Louisa Chard Dunmall, and Dr. Peng Liu, is focused on develop...

We will tell you when either one moves

BounceWatch watches Recolony and VacV Biotherapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Recolony and VacV Biotherapeutics — by email.

Frequently Asked Questions

Recolony — Swiss start-up Recolony aims to develop an oral cancer medication using bacteria.. VacV Biotherapeutics — Developing oncolytic viruses as therapeutics for cancer. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Recolony has raised $160.00K while VacV Biotherapeutics has raised $3.00M.
Recolony and VacV Biotherapeutics operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Recolony with someone else

Start typing a company name or domain.

Related Comparisons

Compiled from the BounceWatch company index. We last looked at Recolony on 25 Jul 2024, and VacV Biotherapeutics on 11 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy